Compare Las Vegas Sands Corp. (LVS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs TG Therapeutics Inc — how do they compare? Las Vegas Sands Corp. trades at $45.56 (market cap $30.36B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Las Vegas Sands Corp. is far larger — about 3.7× TG Therapeutics Inc's market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LVS | TGTX | |
|---|---|---|
Market Cap | $30.36B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $59.06 |
52-Week Low | $44.78 | $26.39 |
Enterprise Value | $42.75B | $8.50B |
Dividend Yield | 2.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.66, up 0.66% on the day, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.91 beating expectations. Revenue growth is robust, reaching $13.02B in 2025, and profitability metrics like a 49.59% gross margin and 94.53% ROE are impressive. The company maintains positive cash flow and recently paid a $0.30 dividend. Analyst sentiment is bullish with a $65.18 consensus price target, though technical indicators suggest near-term pressure.
The outlook for LVS is positive based on fundamental strength and analyst optimism, but risks include high debt levels and bearish technical trends. Investment opportunity lies in its earnings momentum and valuation upside, while investors should monitor debt management and market volatility. The stock's current price near support levels may present a entry point if fundamentals hold.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
